Newly discovered antibody protects against all Covid-19 variants

Researchers at the University of Texas at Austin have identified a new antibody, named SC27, that can neutralize all known variants of SARS-CoV-2, the virus responsible for COVID-19, as well as related coronaviruses. This discovery was part of a study on hybrid immunity, which combines the effects of both infection and vaccination. The antibody was isolated from a single patient and its molecular sequence has been determined, paving the way for potential large-scale production for therapeutic use. The study highlights the importance of SC27 in providing broader protection against evolving COVID-19 variants, which have shown increased resistance to existing vaccines and treatments. The antibody works by binding to the spike protein of the virus, preventing it from attaching to and infecting human cells. The research team utilized advanced technology called Ig-Seq, which combines single-cell DNA sequencing and proteomics, to analyze the antibody response. The findings also suggest that hybrid immunity offers enhanced protection compared to either infection or vaccination alone. As COVID-19 continues to pose a public health challenge, the researchers have filed a patent for SC27, indicating its potential role in future vaccination strategies aimed at achieving universal protection against rapidly mutating viruses.

- A new antibody, SC27, neutralizes all known COVID-19 variants.

- The antibody was isolated from a single patient and its molecular sequence has been identified.

- Hybrid immunity, combining infection and vaccination, provides greater protection than either method alone.

- The research utilized advanced Ig-Seq technology for antibody analysis.

- A patent application for SC27 has been filed, indicating its potential for future treatments.